JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kristal, B. S.
Right arrow Articles by Brown, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kristal, B. S.
Right arrow Articles by Brown, A. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 33, 23169-23175, August 13, 1999


Apoptogenic Ganglioside GD3 Directly Induces the Mitochondrial Permeability Transition*

Bruce S. KristalDagger and Abraham M. Brown

From the Dementia Research Service, Burke Medical Research Institute, White Plains, New York 10605 and the Department of Biochemistry, Cornell University Medical College, New York, New York 10021

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Early events in apoptotic cascades initiated by ceramides or by activation of the surface receptor CD95 (Fas/APO-1) include the formation of ganglioside GD3. GD3 appears to be both necessary and sufficient to propagate this lipid-mediated apoptotic pathway. Later events common to many apoptotic pathways include induction of the mitochondrial permeability transition (PT) and cytochrome c release, which in turn triggers downstream caspases and cell death. The links between GD3 formation and downstream stages of apoptosis are unknown. We report that ganglioside GD3 directly induces the PT in isolated rat liver mitochondria at 30-100 µM in the presence of exogenous substrate (succinate) and at ~3 µM in the absence of exogenous substrate. In contrast, other gangliosides tested (e.g. GM1) have only weak stimulatory effects in the presence of succinate and protect against PT induction in the absence of respiratory substrates. GD3-mediated induction of PT was antagonized by known PT inhibitors, namely cyclosporin A, ADP, trifluoperazine, and Mg2+. GD3 induced PT even in the presence of submicromolar Ca2+; GD3 is therefore the first biological PT inducer identified that does not require elevated Ca2+. Exposure to GD3 also led to mitochondrial cytochrome c release. In contrast, C2-ceramide, which can initiate the lipid-mediated apoptotic cascade in susceptible cells, failed to either induce PT or release cytochrome c. These observations suggest that GD3 propagates apoptosis by inducing the PT and cytochrome c release. This model provides a mechanistic link between the earlier and later stages of CD95-induced/ceramide-mediated apoptosis.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cross-linking of CD95 activates an apoptotic cascade in many cell types, including myeloid and lymphoid cells as well as primary cells from the liver, heart, and lung (1, 2). One branch of this apoptotic cascade is proteolytic (3, 4), whereas the other involves lipid mediators (5-7). Signaling along the lipid pathway is initiated within 5-15 min after CD95 activation by the sequential activation of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase (5-7). Acidic sphingomyelinase-mediated cleavage of sphingolipids produces ceramides, which are themselves sufficient to induce apoptosis in hematopoetic cells (8-11). Cells genetically unable to activate acidic sphingomyelinase (Niemann-Pick lymphoblasts) do not undergo normal CD95-mediated apoptosis; this defect can be bypassed by the addition of exogenous ceramides (12). The lipid-mediated pathway that includes ceramide production may be the most efficient of the multiple pathways that can mediate CD95-induced apoptosis (12-15). TNF1-mediated cytotoxicity also involves ceramide and shares aspects of the upstream apoptotic pathways with CD95 (16-20).

Ceramides appear to require the presence of mitochondria and a "cytosolic factor" to trigger downstream apoptotic events (21). Ceramide elevation during the apoptotic cascade rapidly (5 min) induces the activation of ganglioside GD3 synthase (alpha -2,8-sialyltransferase) within the Golgi (22, 23). This portion of the lipid-mediated pathway appears essential for ceramide-induced apoptosis (12). DeMaria et al. (13) have shown that: 1) activation of GD3 synthase is sufficient to induce apoptosis in cultured lymphoid cells (HuT78), 2) the addition of exogenous GD3 is sufficient to induce apoptosis in HuT78 and myeloid (U937) cells, and 3) inhibition of GD3 synthase is sufficient to prevent CD95-induced apoptosis. These results indicate that GD3 is both necessary and sufficient for CD95- and ceramide-mediated apoptosis.

The immediate downstream targets of GD3 have not been identified. We hypothesize that mitochondria are the immediate downstream target of GD3. Consistent with this is the known transport of gangliosides from the Golgi to the mitochondria (24). This hypothesis is also supported by the observation (13) that GD3-mediated apoptosis includes the loss of mitochondrial membrane potential (Delta Psi ). Loss of Delta Psi is a classic hallmark of the mitochondrial permeability transition (PT) (25-28). Thus, the data suggest that the presence of GD3 may initiate an event or series of events that culminate in the induction of the PT and subsequent activation of the downstream stages of apoptosis.

PT induction has been proposed to contribute to both cellular apoptosis and necrosis in a variety of situations, including ischemia reperfusion, excitotoxicity, and T-lymphocyte cell death (29-34). The PT involves the opening of a pore in the inner mitochondrial membrane that allows free diffusion of solutes with mass under 1500 daltons (25-27, 35-37). PT induction abolishes oxidative phosphorylation, leads to loss of the mitochondrial proton gradient, and allows efflux of mitochondrially sequestered calcium into the cytoplasm (25-27, 35-37). These consequences on energy metabolism and calcium homeostasis, as well as the biochemical identity of the first PT inducers studied (high calcium, oxidants, inorganic phosphate), led to a recognition of the probable role of PT in ischemia reperfusion injury (29).

The involvement of PT in apoptosis has been recognized more recently. The PT has been proposed to propagate the apoptotic cascade by triggering the mitochondrial release of apoptosis inducing factor, which stimulates nuclear fragmentation, and cytochrome c, which activates the downstream caspases that effect the end stage of apoptosis (38-41). Several lines of evidence converge to support the view that the PT propagates the downstream stages of apoptosis mediated by the lipid-dependent pathway that includes ceramide and GD3. First, studies in cell-free systems indicate that PT is sufficient to induce the downstream stages of apoptosis (42). Second, loss of Delta Psi , a hallmark of the PT, can precede and correlate with various markers of apoptotic cell death induced by this family of inducers (CD95, TNF, ceramide, GD3) (13, 43). Third, cyclosporin A (CsA), the best established pharmacologic PT inhibitor, delays or prevents the progression of induced apoptosis in cultured cells (34, 44). Fourth, treatment with CsA delays the loss of Delta Psi during apoptosis mediated by TNF and ceramide (43). Fifth, TNF-induced cytotoxicity in L929 cells, which may occur via apoptosis and/or necrosis (45, 46), is mediated by ceramide. Cytotoxicity in this model is delayed by PT inhibitors, suggesting the involvement of PT in cell death (47, 48).

We tested the hypothesis that GD3 directly mediates PT induction by examining the ability of GD3 and related compounds to induce the PT. Data presented demonstrate that GD3, but not other gangliosides or C2-ceramide, accelerated the PT in isolated rat liver mitochondria in either the presence or absence of exogenous substrate. Strikingly, GD3 was capable of inducing the PT in the presence of submicromolar Ca2+. GD3 is therefore the first physiological inducer clearly shown not to require elevated Ca2+. Furthermore, GD3, but not C2-ceramide, induced the release of cytochrome c from mitochondria. These results are consistent with our hypothesis that GD3 itself directly enlists mitochondria into the apoptotic cascade.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mitochondrial Isolation-- Liver mitochondria were isolated from 4-6 month old male Fischer 344 rats essentially as described previously (49). Briefly, livers were rapidly homogenized in ice-cold isolation buffer (250 mM mannitol, 75 mM sucrose, 100 µM K-EDTA, 10 mM K-HEPES, pH 7.4) supplemented with 500 µM K-EGTA (pH 7.4). Homogenates were centrifuged at 1000 × g for 10 min. Supernatants were removed and centrifuged at 10,000 × g for 15 min. Pellets were washed three times in isolation buffer supplemented with 0.5% fatty acid-free bovine serum albumin (Sigma A-6003). The first wash buffer was also supplemented with 500 µM EGTA. The final mitochondrial pellet was resuspended in the same buffer without EGTA or bovine serum albumin.

PT Induction-- PT induction was assessed spectrophotometrically essentially as described previously (49, 50) by suspending ~0.1-0.2 mg of mitochondrial protein at room temperature in 200 µl of 215 mM mannitol, 71 mM sucrose, 5 mM K-HEPES (pH 7.4) in the presence (or, where indicated, absence) of 10 mM sodium succinate. Gangliosides (Alexis, Matreya) were dissolved in water. C2-ceramide (Biomol) was dissolved in ethanol, and the appropriate concentrations of ethanol (<= 1.5%) were added to controls run in parallel with ceramide samples. Changes in absorbance at 540 nm (A540) were followed for 2 h using a SpectraMax 250 Plate Reader (Molecular Dynamics).

Divalent Cation Measurement and Buffer Preparation-- The total divalent cation concentration present in the buffer was estimated by a spectrophotometric sequestration assay to be ~5 µM (60% of which, ~3 µM, was Ca2+) using 2.5 µM of the indicators Mag-Fura-2 and Fura Red and the cation chelators EDTA, EGTA, and tetrakis(2-pyridylmethyl)ethylenediamine. Results for Ca2+ concentrations determined by this method are consistent with atomic absorption studies.

Use of this method revealed that preparing buffers from most standard research grade chemicals and deionized water led to levels of divalent cations, particularly Ca2+, which were unacceptable (as high as ~30 µM Ca2+). We therefore prepared all buffers from deionized water (>15 megohm) and the highest purity reagents available.

Western Blotting-- Mitochondrial supernatants and pellets were collected following a 5-min centrifugation (~14,000 × g). Western blotting was done using minor modifications of established procedures. Proteins were separated using 4-20% Tris-tricine polyacrylamide gels. Following transfer, membranes were blocked for 1 h in 5% fetal calf sera, 0.2% bovine serum albumin, and 0.5% Tween 20 in phosphate-buffered saline. Incubations with primary antibody were carried out overnight at a dilution of 1:2000. Incubations (30 min) with goat anti-mouse, alkaline phosphatase conjugate (Bio-Rad) were also carried out at a dilution of 1:2000. Nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (Bio-Rad) were used as substrates according to the supplier's instructions. All incubations were carried out at room temperature.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

GD3 Directly Induces the PT-- PT induction in liver mitochondria isolated from male Fischer 344 rats was monitored spectrophotometrically as loss of absorbance using established methods (49, 50). Concentrations of GD3 >= 3 µM increased the rate of PT induction in the absence of exogenous substrate (Fig. 1, A and B). This dose of GD3 (3 µM) is ~40-fold lower than that required to induce apoptotic cell death in 50% of cultured HuT78 cells at 24 h (13). The ability of GD3 to accelerate induction was most notable in the absence of added Ca2+ (i.e. total Ca2+ ~3 µM, see "Experimental Procedures"). Indeed, >= 12 µM exogenous Ca2+ (~15 µM total) induced PT in the absence of GD3 with such rapid kinetics that additional effects of GD3 were undetectable (Fig. 1C).


View larger version (53K):
[in this window]
[in a new window]
  		Fig. 1.   GD3 promotes but GD1a, GM1, and GT1 inhibit PT induction. Representative traces from a minimum of three experiments on the effects of GD3 (A-C) or GD1a, GM1, and GT1b (D-F) on PT induction in the absence of exogenous succinate. Induction by Ca2+ was studied in liver mitochondria isolated from 4-6-month-old male Fischer 344 rats (49). As noted under "Experimental Procedures," the basic buffer contains ~3 µM Ca2+. The efficacy of 30 µM GD3 to promote PT induction varied from rat to rat; the greatest response observed for this dose is shown. In all figures, data for all traces in a single panel were collected at the same time from the same mitochondrial preparation. In all figures, data are representative of studies on 3-10 independent mitochondrial preparations.

The ability of gangliosides GD1a, GM1, and GT1b to induce PT was examined to control for nonspecific effects of gangliosides, such as the effects on lipid organization or ion permeability (51, 52). These gangliosides do not to induce apoptosis in the HuT78 system (13). Unlike GD3, gangliosides (GD1a, GM1, or GT1b) delayed PT induction at 30 µM and completely prevented induction at 100 µM (Fig. 1D). Some protection persisted even at higher Ca2+ concentrations (Fig. 1, E and F).

Ganglioside specificity was maintained in the presence of exogenous substrate, although the concentration of GD3 required to induce PT increased 10-30-fold. In the presence of 10 mM succinate, which increases mitochondrial resistance to PT induction, 100 µM GD3 rapidly induced PT at all calcium concentrations tested (Fig. 2, A-D); 3-10 µM GD3 accelerated PT induction when total Ca2+ was ~27 µM (i.e. 24 µM added Ca2+, Fig. 2D), a concentration typically used for PT studies. Gangliosides GD1a, GT1b, and GM1 had only minimal effects until total calcium was ~27 µM (Fig. 2, E-H), again demonstrating a specific response to GD3.


View larger version (41K):
[in this window]
[in a new window]
  		Fig. 2.   GD3, but not other gangliosides, promotes PT induction in the presence of succinate. Representative traces from a minimum of three experiments on the effects of ganglioside GD3 (A-D) or gangliosides GD1a, GM1, and GT1b (E-H) on PT induction in the presence of 10 mM succinate.

In contrast to GD3, C2-ceramide had no consistent effects on PT induction in either the presence or absence of exogenous substrate (Fig. 3), even at concentrations of C2-ceramide 4-fold higher than those that induce cellular apoptosis (12). In some cases, such as that shown in Fig. 3A, C2-ceramide actually delayed PT induction. Similar results were observed in the presence of increased Ca2+ (not shown).


View larger version (15K):
[in this window]
[in a new window]
  		Fig. 3.   In contrast to GD3, C2-ceramide does not promote PT induction. Representative traces showing the effects of C2-ceramide on PT induction in the absence (panel A) or presence (panel B) of exogenous succinate.

GD3-Ca2+ Interactions-- Our studies show that GD3 acted synergistically with free Ca2+ to induce PT. GD3 induction was enhanced by added Ca2+ in the presence of either endogenous substrate (Fig. 1, A-C, and Fig. 4, traces D-F) or added succinate (Fig. 2, C and D). These data are consistent with previous studies that suggested the necessity of Ca2+ as a co-factor in PT induction (25-27). The combined effect of GD3 and Ca2+ on PT induction is saturable. For example, when the PT was induced in the presence of total Ca2+, >= 15 µM, additional effects of GD3 were nearly undetectable (Fig. 1C and Fig. 4A-E, F traces). Similarly, 30 or 100 µM GD3 were insensitive to Ca2+ addition (Fig. 4, D and E). This saturation property of GD3 is unlike the interaction of other inducers with Ca2+.


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 4.   GD3 induction does not require supraphysiological Ca2+. Representative traces showing the effects of GD3 on PT induction in the absence of exogenous succinate. All traces in this figure are from a single mitochondrial preparation and were done simultaneously. Note that traces D-F in each panel are also in Fig. 1. The addition of 12 (trace C), 24 (trace B), or 36 µM (trace A) EGTA results in calculated Ca2+ of ~5, 2, or 1 pM, respectively. No addition (trace D) or the addition of 6 (trace E) or 12 µM (trace F) Ca2+ lead to total predicted free Ca2+ of ~3, 9, and 15 µM, respectively.

Because the potency of GD3 as a PT inducer became more apparent as less Ca2+ was added, we further probed the interactions between GD3 and Ca2+. These data show that GD3 also acted independently of free Ca2+ to induce PT. Free Ca2+ contributed by buffer components (~3 µM) was reduced by adding 12, 24, or 36 µM of the divalent cation chelator EGTA (Kd, 10-10.86 for Ca2+; calculated free Ca2+, ~5, 2, or 1 pM, respectively). The addition of 12 µM EGTA, which reduces free Ca2+ to ~5 pM, prevented spontaneous PT induction in controls (no GD3) for at least 2 h (Fig. 4A). Treatment with >= 10 µM GD3 overcame the EGTA-mediated protection (Fig. 4A-C, C traces). Higher doses of EGTA progressively delayed, but did not prevent, GD3-mediated PT induction (Figs. 4A, A and B traces, and 5C). GD3 also induced PT with subpicomolar free Ca2+ in the presence of succinate (Fig. 5D).


View larger version (52K):
[in this window]
[in a new window]
  		Fig. 5.   The effects of GD3 are because of PT induction. Well characterized inhibitors of the PT, CsA (A and B), MgCl2, EGTA (C and D), ADP (E and F), and trifluoperazine (G and H) all delay PT induction by GD3 in both the absence (A, C, E, and G) and presence (B, D, F, and H) of succinate.

Inhibitors Confirm PT Induction-- We wished to confirm that the optical changes were because of PT induction and not a nonspecific loss of absorbance. We therefore tested the efficacy of four well characterized inhibitors of the PT, CsA, MgCl2, ADP, and trifluoperazine (25-27, 53) to prevent GD3-mediated effects (Fig. 5).

CsA-- In the absence of succinate, 5 µM CsA, but not 0.5 µM CsA, prevented PT induction by 100 µM GD3 (Fig. 5A, traces AH, BH, and CH). Both doses of CsA protected against 10 µM GD3 (Fig. 5A, traces AL, BL, and CL). In the presence of succinate, both 0.5 and 5 µM CsA delayed GD3-induced PT but did not prevent it (Fig. 5B). The higher CsA dose consistently protected, whereas only some preparations were protected by the lower dose.

MgCl2-- The addition of 3 mM MgCl2 or 100 µM EGTA resulted in essentially equal inhibition in either the presence or absence of succinate (compare traces B and C in Fig. 5, C or D). This finding suggests that MgCl2 acted by inhibiting a divalent cation-dependent event, consistent with the known role of MgCl2 as a competitive inhibitor of the calcium uniporter. Note that GD3 induction in the presence of 100 µM EGTA is further delayed relative to induction in the presence of 36 µM EGTA (Fig. 4A-E, A traces).

ADP-- In either the presence or absence of succinate, ADP prevented PT induction by 100 µM GD3 (Fig. 5, E and F).

Trifluoperazine-- The phospholipase A2 inhibitor trifluoperazine prevented GD3-mediated PT in both the presence and absence of succinate (Fig. 5, G and H). Protection was dose-dependent, and the protective doses corresponded with those that blocked Ca2+-mediated PT induction (not shown).

The inhibitor data shown (Fig. 5) confirm that the GD3-mediated loss of absorbance is because of the induction of the PT.

GD3 Releases Cytochrome c-- Further support for the hypothesis that GD3 can directly enlist mitochondria into the apoptotic cascade is that GD3-mediated PT induction released mitochondrial cytochrome c (Fig. 6). In contrast, cytochrome c was not released from mitochondria in either control or C2-ceramide-treated samples. Release was more variable and less complete in the absence of succinate, suggesting that mitochondrial respiration may promote the release of cytochrome c. This possibility is under further investigation.


View larger version (42K):
[in this window]
[in a new window]
  		Fig. 6.   GD3, but not C2-ceramide, releases cytochrome c. Mitochondrial pellets (0.1-0.2 mg of protein (P)) and their respective supernatants (S) were analyzed by Western blotting using an antibody that recognizes a denatured epitope of cytochrome c (Zymed Laboratories Inc.). Sample volumes were adjusted so that the P and S lanes correspond to equal mitochondrial reaction volumes (or masses). A shows the release in the presence of succinate; B shows the release in the absence of exogenous substrate. C demonstrates antibody specificity by showing the results obtained following pre-incubation of the primary antibody with a 50-fold molar excess of denatured, purified, rat cytochrome c (Sigma). Lane pairs are as labeled, and the final lane is purified cytochrome c. Equivalent results were also obtained using a rabbit antisera to cytochrome c (Santa Cruz Biotechnology).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

GD3 Displays Structural Specificity as a PT Inducer-- Under the conditions used in this study, GD3 induced a dose-dependent loss of absorbance (Figs. 1, 2, and 4). Use of a series of inhibitors (CsA, MgCl2, ADP, and trifluoperazine; Fig. 5) confirmed that this loss of absorbance resulted from induction of the PT. In contrast, related gangliosides such as GD1a, GM1, or GT1b, which do not induce cell death, failed to induce PT (Figs. 1 and 2). The structural specificity of the sialogangliosides in PT induction is reminiscent of that observed for hydroxyalkenals, where 4-hydroxyhexenal induces the PT at femtomolar levels, but 4-hydroxynonenal requires micromolar concentrations (49). The protective action of GM1 may contribute to the protective capacity of this compound to prevent cell death in many systems, including models of ischemia (54, 55).

Ceramides can induce both apoptotic and necrotic cell death that are associated with mitochondrial dysfunction, including the loss of Delta Psi (8-12, 56). We have demonstrated that biologically active C2-ceramide has little or no direct effect on PT induction or cytochrome c release in isolated mitochondria (Figs. 3 and 6). This result differs from a previous report that C2-ceramide can induce PT in isolated liver mitochondria (56). The differences may be because of important differences in experimental conditions. The other study used digitonin-treated mitochondria that were purified using a Percoll gradient and assayed in the presence of phosphate, rotenone, and oligomycin.

GD3 Acts Both Synergistically with Ca2+ and Independently of Ca2+ to Induce PT-- In vitro studies in isolated mitochondria have provided predictive insight into PT induction in cells. However, the PT inducers previously identified by studies in isolated mitochondria, with the exception of the nonphysiologic thiol cross-linking agent phenylarsine oxide, require supraphysiological levels of calcium (e.g. >= 25 µM). Therefore, in vivo PT induction, which occurs without such a profound increase in intracellular Ca2+, must be stimulated by an unidentified component. Our study shows that GD3 may be such a compound.

In addition to acting synergistically with Ca2+ to induce PT (Figs. 1, 2, and 4), GD3 can also act independently of free Ca2+ to induce PT (Fig. 4). This behavior is unlike that previously described for naturally occurring PT inducers (25-27). The ability of GD3 to induce PT in the presence of submicromolar Ca2+ is important, because intracellular levels of Ca2+ do not rise above 0.4 µM during the early stages of CD95-mediated apoptosis (57, 58).

Overall, the data presented suggest a biphasic interaction between GD3, divalent cations, and the PT. One phase is apparent when free Ca2+ varies from 0-15 µM (traces C-F in all panels of Fig. 4) and presumably reflects the effects of Ca2+ transported by the mitochondrial uniporter (e.g., Ca2+ accumulation/cycling) (26). The second phase occurs when free Ca2+ varies in the picomolar range, which is well below the concentration at which the mitochondrial Ca2+ uniporter acts (26). GD3-mediated PT induction was progressively delayed by increasing EGTA from 12 to 100 µM (Figs. 4, traces A-C, and 5C). A possible explanation for the second phase is that GD3-mediated PT requires a divalent cation that either GD3 or mitochondria bind with an affinity comparable to that of EGTA.

PT Induction by GD3 Can Enlist Mitochondria Into the Apoptotic Cascade-- The data presented for isolated mitochondria link GD3 to PT induction (Figs. 1, 2, 4, and 5) and cytochrome c release in vitro (Fig. 6). These data are analogous to data from cell culture studies that link GD3 to the loss of Delta Psi and subsequent apoptotic cell death in vivo (13). Specifically, in cultured cells, elevation of intracellular GD3, whether by synthesis or exogenous addition, is correlated with a loss of Delta Psi and (other) downstream events associated with progression through the lipid-mediated apoptotic pathway (13). We demonstrated that exposure to GD3 directly induced the PT, which abolishes Delta Psi , and released cytochrome c, which can propogate the apoptotic cascade. These data are consistent with reports that PT induction results in cytochrome c release (59, 60). These data also confirm that GD3-mediated PT leads to the release of at least one of the apoptogenic factors associated with activation of downstream caspases. Our data thus support the hypothesis that the mechanism by which GD3 propagates the lipid-mediated apoptotic pathway is a direct induction of the PT (Figs. 1 and 2) and release of mitochondrial cytochrome c (Fig. 6).

Conclusions-- Evidence of GD3-mediated PT induction and cytochrome c release provide a biochemical mechanism linking the early and late stages of CD95-mediated and ceramide-induced apoptosis. The data presented indicate that PT induction and apoptosis can be propagated by the formation of GD3 independent of elevated free intracellular Ca2+. This contrasts with previous work that focused on models in which the PT was driven primarily by high Ca2+. Although Ca2+ appears to be unnecessary in GD3-mediated PT, our data demonstrate that elevated intracellular Ca2+ can synergistically accelerate PT induction both in the presence and in the absence of exogenous respiratory substrates. The observed capacity for synergy between Ca2+ and GD3 in PT induction provides a mechanism by which elevated intracellular Ca2+ may contribute to various forms of cell death involving lipid mediators. These include apoptosis, and probably necrosis, initiated by the activation of CD95 or the TNF receptor as well as cell death subsequent to radiation exposure or HIV infection (8, 9). Further investigations are needed to determine the mechanisms by which different gangliosides modulate induction or inhibition of PT and the recruitment of mitochondria into the apoptotic cascade.

    ACKNOWLEDGEMENTS

We thank Drs. John Blass, Arthur Cooper, Gary Gibson, and Rex Sheu for their comments on the manuscript and Alison Moskowitz for assistance in preparing mitochondria.

    Addendum

During review of this manuscript, we have become aware that observations of PT induction by ganglioside GD3 have also been made in the laboratory of Dr. Paolo Bernardi (Scorrano, L., Petronilli, V., DiLisa, F., Bernardi, P. (1999) J. Biol. Chem. 274, in press).

    FOOTNOTES

* This work was partially supported by Grant AG15354 from the NIA, National Institutes of Health (to B. S. K.), Leadership and Excellence in Alzheimer's Disease (LEAD) Award AG09014 from the NIA, National Institutes of Health (Blass), and by the Winifred Masterson Burke Relief Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dementia Research Service, Burke Medical Research Inst., 785 Mamaroneck Ave., White Plains, NY 10605.

    ABBREVIATIONS

The abbreviations used are: TNF, tumor necrosis factor; PT, permeability transition; CsA, cyclosporin A.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Nagata, S., and Golstein, P. (1995) Science 267, 1449-1456[Abstract/Free Full Text]
2. Krammer, P. H. (1996) Cell Death Diff. 3, 159-160
3. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O' Rourke, K., Shevchenko, A., Carsten-Scaffidi, J. N., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., and Dixit, V. M. (1996) Cell 85, 817-827[CrossRef][Medline] [Order article via Infotrieve]
4. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. (1996) Cell 85, 803-815[CrossRef][Medline] [Order article via Infotrieve]
5. Testi, R. (1996) Trends Biochem. Sci. 21, 468-471[CrossRef][Medline] [Order article via Infotrieve]
6. Cifone, M. G., De Maria, R., Roncaioli, P., Rippo, M. R., Azuma, M., Lanier, L. L., Santoni, A., and Testi, R. (1994) J. Exp. Med. 180, 1547-1552[Abstract/Free Full Text]
7. Gulbins, E., Bissonette, R., Mahboubi, A., Martin, S., Nishioka, W., Brunner, T., Baier, G., Baier-Bitterlich, G., Byrd, C., and Lang, F. (1995) Immunity 2, 341-351[CrossRef][Medline] [Order article via Infotrieve]
8. Hannun, Y. A., and Obeid, L. M. (1995) Trends Biochem. Sci. 20, 73-77[CrossRef][Medline] [Order article via Infotrieve]
9. Obeid, L. M., Linardic, C. M., Karolak, L. A., and Hannun, Y. A. (1993) Science 259, 1769-1771[Abstract/Free Full Text]
10. Cifone, M. G., Roncaioli, P., De Maria, R., Camarda, G., Santoni, A., Ruberti, G., and Testi, R. (1995) EMBO J. 14, 5859-5868[Medline] [Order article via Infotrieve]
11. Kolesnick, R., and Fuks, Z. (1995) J. Exp. Med. 181, 1949-1952[Free Full Text]
12. De Maria, R., Rippo, M. R., Schuchman, E. H., and Testi, R. (1998) J. Exp. Med. 187, 897-902[Abstract/Free Full Text]
13. De Maria, R., Lenti, L., Malisan, F., d'Agostino, F., Tomassini, B., Zeuner, A., Rippo, M. R., and Testi, R. (1997) Science 277, 1652-1655[Abstract/Free Full Text]
14. Susin, S. A., Zamzami, N., Castedo, M., Daugas, E., Wang, H.-G., Galey, S., Fassy, F., Reed, J. C., and Kroemer, G. (1997) J. Exp. Med. 186, 25-37[Abstract/Free Full Text]
15. Kuwana, T., Smith, J. J., Muzio, M., Dixit, V., Newmeyer, D. D., and Kornbluth, S. (1998) J. Biol. Chem. 273, 16589-16594[Abstract/Free Full Text]
16. Dong, J., Naito, M., Mashima, T., Jang, W. H., and Tsuruo, T. J. (1998) J. Cell Physiol. 174, 179-185[CrossRef][Medline] [Order article via Infotrieve]
17. Adam-Klages, S., Schwandner, R., Adam, D., Kreder, D., Bernardo, K., and Kronke, M. (1998) J. Leukocyte Biol. 63, 678-682[Abstract]
18. Bezombes, C., Maestre, N., Laurent, G., Levade, T., Bettaieb, A., and Jaffrezou, J. P. (1998) FASEB J. 12, 101-109[Abstract/Free Full Text]
19. Gamard, C. J., Dbaibo, G. S., Liu, B., Obeid, L. M., and Hannun, Y. A. (1997) J. Biol. Chem. 272, 16474-16481[Abstract/Free Full Text]
20. Dbaibo, G. S., Perry, D. K., Gamard, C. J., Platt, R., Poirier, G. G., Obeid, L. M., and Hannun, Y. A. (1997) J. Exp. Med. 185, 481-490[Abstract/Free Full Text]
21. Susin, S. A., Zamzami, N., Larochette, N., Dallaporta, B., Marzo, I., Brenner, C., Hirsch, T., Petit, P. X., Geuskens, M., and Kroemer, G. (1997) Exp. Cell Res. 236, 397-403[CrossRef][Medline] [Order article via Infotrieve]
22. Allan, D., and Kallen, K. J. (1993) Prog. Lipid Res. 32, 195-219[CrossRef][Medline] [Order article via Infotrieve]
23. van Echten, G., and Sandhoff, K. (1993) J. Biol. Chem. 268, 5341-5344[Free Full Text]
24. Matyas, G. R., and Morre, D. J. (1987) Biochim. Biophys. Acta 921, 599-614[Medline] [Order article via Infotrieve]
25. Zoratti, M., and Szabo, I. (1995) Biochim. Biophys. Acta 1241, 139-176[Medline] [Order article via Infotrieve]
26. Gunter, T. E., Gunter, K. K., Sheu, S. S., and Gavin, C. E. (1994) Am. J. Physiol. 267, C313-C339[Abstract/Free Full Text]
27. Bernardi, P., Broekemeier, K. M., and Pfeiffer, D. R. (1994) J. Bioenerg. Biomembr. 26, 509-517[CrossRef][Medline] [Order article via Infotrieve]
28. Bernardi, P. (1992) J. Biol. Chem. 267, 8834-8839[Abstract/Free Full Text]
29. Duchen, M. R., McGuiness, O., Brown, L. A., and Crompton, M. (1993) Cardiovasc. Res. 27, 1790-1794[Free Full Text]
30. Siesjo, B., and Siesjo, P. (1996) Eur. J. Anaesthesiol. 13, 247-268[CrossRef][Medline] [Order article via Infotrieve]
31. Nieminen, A. L., Petrie, T. G., Lemasters, J. J., and Selman, W. R. (1996) Neuroscience 75, 993-997[CrossRef][Medline] [Order article via Infotrieve]
32. White, R. J., and Reynolds, I. J. J. (1996) Neuroscience 16, 5688-5697[Abstract/Free Full Text]
33. Schinder, A. F., Olson, E. F., Spitzer, N. C., and Montal, M. (1996) J. Neurosci. 16, 6125-6133[Abstract/Free Full Text]
34. Castedo, M., Hirsch, T., Susin, S. A., Zamzami, N., Marchetti, P., Macho, A., and Kroemer, G. (1996) J. Immunol. 157, 512-521[Abstract]
35. Schlegel, J., Schweizer, M., and Richter, C. (1992) Biochem. J. 285, 65-69
36. Kristal, B. S., and Dubinsky, J. M. (1997) J. Neurochem. 69, 524-538[Medline] [Order article via Infotrieve]
37. Broekemeier, K. M., and Pfeiffer, D. R. (1989) Biochem. Biophys. Res. Commun. 163, 561-566[CrossRef][Medline] [Order article via Infotrieve]
38. Green, D. R., and Reed, J. C. (1998) Science 281, 1309-1312[Abstract/Free Full Text]
39. Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Constantini, P., Loeffler, M., Larochette, N., Goodlett, D. R., Aebersold, R., Siderovski, D. P., Penninger, J. M., and Kroemer, G. (1999) Nature 397, 441-446[CrossRef][Medline] [Order article via Infotrieve]
40. Scarlett, J. L., and Murphey, M. P. (1997) FEBS Lett. 418, 282-286[CrossRef][Medline] [Order article via Infotrieve]
41. Petit, P. X., Goubern, M., Diolez, P., Susin, S. A., Zamzami, N., and Kroemer, G. (1998) FEBS Lett. 426, 111-116[CrossRef][Medline] [Order article via Infotrieve]
42. Zamzami, N., Susin, S. A., Marchetti, P., Hirsch, T., Gomez-Monterrey, I., Castedo, M., and Kroemer, G. (1996) J. Exp. Med. 183, 1533-1544[Abstract/Free Full Text]
43. Zamzami, N., Marchetti, P., Castedo, M., Decaudin, D., Macho, A., Hirsch, T., Susin, S. A., Petit, P. X., Mignotte, B., and Kroemer, G. (1995) J. Exp. Med. 182, 367-377[Abstract/Free Full Text]
44. Kroemer, G., Zamzami, N., and Susin, S. A. (1997) Immunol. Today 18, 44-51[CrossRef][Medline] [Order article via Infotrieve]
45. Sánchez-Alcázar, J. A., Ruiz-Cabello, J., Hernandez-Munoz, I., Pobre, P. S., de la Torre, P., Siles-Rivas, E., Garcia, I., Kaplan, O., Munoz-Yague, M. T., and Solis-Herruzo, J. A. (1997) J. Biol. Chem. 272, 30167-30177[Abstract/Free Full Text]
46. Fady, C., Gardner, A., Jacoby, F., Briskin, K., Tu, Y., Schmid, I., and Lichtenstein, A. (1995) J. Interferon Cytokine Res. 15, 71-80[Medline] [Order article via Infotrieve]
47. Hehner, S. P., Hofmann, T. G., Ratter, F., Dumont, A., Dröge, W., and Schmitz, M. L. (1998) J. Biol. Chem. 273, 18117-18121[Abstract/Free Full Text]
48. Pastorino, J. G., Simbula, G., Yamamoto, K., Glascott, P. A., Jr., Rothman, R. J., and Farber, J. L. (1996) J. Biol. Chem. 271, 29792-29798[Abstract/Free Full Text]
49. Kristal, B. S, Park, B. K., and Yu, B. P. (1996) J. Biol. Chem. 271, 6033-6038[Abstract/Free Full Text]
50. Rigobello, M. P., Toninello, A., Siliprandi, D., and Bindoli, A. (1993) Biochem. Biophys. Res. Commun. 194, 1276-1281[CrossRef][Medline] [Order article via Infotrieve]
51. Sarti, P., Antonini, G., Malatesta, F., Vallone, B., Brunori, M., Masserini, M., Palestini, P., and Tettamanti, G. (1990) Biochem. J. 267, 413-416[Medline] [Order article via Infotrieve]
52. Tettamanti, G., and Riboni, L. (1994) Prog. Brain Res. 101, 77-100[Medline] [Order article via Infotrieve]
53. Pereira, R. S., Bertocchi, A. P. F., and Vercesi, A. E. (1992) Biochem. Pharmacol. 44, 1795-1801[CrossRef][Medline] [Order article via Infotrieve]
54. Hadjiconstantinou, M., and Neff, N. H. (1998) J. Neurochem. 70, 1335-1345[Medline] [Order article via Infotrieve]
55. Weber, M., Mohand-Said, S., Hicks, D., Dreyfus, H., and Sahel, J. A. (1996) Invest. Ophthalmol. Visual Sci. 37, 267-273[Abstract/Free Full Text]
56. Arora, A. S., Jones, B. J., Patel, T. C., Bronk, S. F., and Gores, G. J. (1997) Hepatology 25, 958-963[CrossRef][Medline] [Order article via Infotrieve]
57. Oshimi, Y., Oshimi, K., and Miyazaki, S. (1996) J. Physiol. (Lond.) 495, 319-329[Medline] [Order article via Infotrieve]
58. Oshimi, Y., and Miyazaki, S. (1995) J. Immunol. 154, 599-609[Abstract]
59. Kantrow, S. P., and Piantadosi, C. A. (1997) Biochem. Biophys. Res. Commun. 232, 669-671[CrossRef][Medline] [Order article via Infotrieve]
60. Yang, J. C., and Cortopassi, G. A. (1998) Free Radical Biol. Med. 24, 624-631[CrossRef][Medline] [Order article via Infotrieve]

Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
S. A. Novgorodov, T. I. Gudz, and L. M. Obeid
Long-chain Ceramide Is a Potent Inhibitor of the Mitochondrial Permeability Transition Pore
J. Biol. Chem., September 5, 2008; 283(36): 24707 - 24717.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
W.-h. Zhang, H. Wang, X. Wang, M. V. Narayanan, I. G. Stavrovskaya, B. S. Kristal, and R. M. Friedlander
Nortriptyline Protects Mitochondria and Reduces Cerebral Ischemia/Hypoxia Injury
Stroke, February 1, 2008; 39(2): 455 - 462.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. G. Gazaryan, I. P. Krasinskaya, B. S. Kristal, and A. M. Brown
Zinc Irreversibly Damages Major Enzymes of Energy Production and Antioxidant Defense Prior to Mitochondrial Permeability Transition
J. Biol. Chem., August 17, 2007; 282(33): 24373 - 24380.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. E. Fox, X. Han, S. Kelly, A. H. Merrill Jr., R. E. Martin, R. E. Anderson, T. W. Gardner, and M. Kester
Diabetes Alters Sphingolipid Metabolism in the Retina: A Potential Mechanism of Cell Death in Diabetic Retinopathy
Diabetes, December 1, 2006; 55(12): 3573 - 3580.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
W.-K. Lee and F. Thevenod
A role for mitochondrial aquaporins in cellular life-and-death decisions?
Am J Physiol Cell Physiol, August 1, 2006; 291(2): C195 - C202.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J.-S. Kim, Y. Jin, and J. J. Lemasters
Reactive oxygen species, but not Ca2+ overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion
Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2024 - H2034.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. J. Dilda, S. Decollogne, M. Rossiter-Thornton, and P. J. Hogg
Para to Ortho Repositioning of the Arsenical Moiety of the Angiogenesis Inhibitor 4-(N-(S-Glutathionylacetyl)Amino)Phenylarsenoxide Results in a Markedly Increased Cellular Accumulation and Antiproliferative Activity
Cancer Res., December 15, 2005; 65(24): 11729 - 11734.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. W. Retter, J. C. Johnson, D. W. Peckham, J. E. Bannink, C. S. Bangur, K. Dresser, F. Cai, T. M. Foy, N. A. Fanger, G. R. Fanger, et al.
Characterization of a Proapoptotic Antiganglioside GM2 Monoclonal Antibody and Evaluation of Its Therapeutic Effect on Melanoma and Small Cell Lung Carcinoma Xenografts
Cancer Res., July 15, 2005; 65(14): 6425 - 6434.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. A. Novgorodov, Z. M. Szulc, C. Luberto, J. A. Jones, J. Bielawski, A. Bielawska, Y. A. Hannun, and L. M. Obeid
Positively Charged Ceramide Is a Potent Inducer of Mitochondrial Permeabilization
J. Biol. Chem., April 22, 2005; 280(16): 16096 - 16105.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Johans, E. Milanesi, M. Franck, C. Johans, J. Liobikas, M. Panagiotaki, L. Greci, G. Principato, P. K. J. Kinnunen, P. Bernardi, et al.
Modification of Permeability Transition Pore Arginine(s) by Phenylglyoxal Derivatives in Isolated Mitochondria and Mammalian Cells: STRUCTURE-FUNCTION RELATIONSHIP OF ARGININE LIGANDS
J. Biol. Chem., April 1, 2005; 280(13): 12130 - 12136.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
R. J. Ferrante, H. Ryu, J. K. Kubilus, S. D'Mello, K. L. Sugars, J. Lee, P. Lu, K. Smith, S. Browne, M. F. Beal, et al.
Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington's Disease
J. Neurosci., November 17, 2004; 24(46): 10335 - 10342.
[Abstract] [Full Text] [PDF]